Page 1461 - Williams Hematology ( PDFDrive )

1436 Part X: Malignant Myeloid Diseases <CN>: <ct> PB

1265. Legrand O, Simonin G, Zittoun R, Marie JP: Lung resistance protein (LRP) gene 1293. van der Velden VH, Hochhaus A, Cazzaniga G, et al: Detection of minimal resid-
expression in adult acute myeloid leukemia: A critical evaluation by three techniques. ual disease in hematologic malignancies by real-time quantitative PCR: Principles,
Leukemia 12:1367, 1998. approaches, and laboratory aspects. Leukemia 17:1013, 2003.
1266. Filipits M, Pohl G, Stranzl T, et al: Expression of the lung resistance protein predicts 1294. Kern W, Haferlach C, Haferlach T, Schnittger S: Monitoring of minimal residual
poor outcome in de novo acute myeloid leukemia. Blood 91:1508, 1998. disease in acute myeloid leukemia. Cancer 112:4, 2008.
1267. Gale RP, Horowitz MM, Weiner RS, et al: Impact of cytogenetic abnormalities on out- 1295. Gal H, Amariglio N, Trakhtenbrot L, et al: Gene expression profiles of AML derived
come of bone marrow transplants in acute myelogenous leukemia in first remission. stem cells; similarity to hematopoietic stem cells. Leukemia 20:2147, 2006.
Bone Marrow Transplant 16:203, 1995. 1296. Laczika K, Novak M, Hilgarth B, et al: Competitive CBFbeta/MYH11 reverse-
1268. Zapatero A, Martin de Vidales C, Pinar B, et al: Prognostic factors affecting leukemia transcriptase polymerase chain reaction for quantitative assessment of minimal
relapse after allogeneic BMT conditioned with cyclophosphamide and fractionated residual disease during postremission therapy in acute myeloid leukemia with inver-
TBI. Bone Marrow Transplant 18:591, 1996. sion(16): A pilot study. J Clin Oncol 16:1519, 1998.
1269. Sievers EL, Loken MR: Detection of minimal residual disease in acute myelogenous 1297. Marucci G, Caligiuri MA, Dohner H, et al: Quantification of CBFbeta/MYH11 fusion
leukemia. J Pediatr Hematol Oncol 17:123, 1995. transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia.
1270. Schnittger S, Weisser M, Schoch C, et al: New score predicting for prognosis in PML- Leukemia 15:1072, 2001.
RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantifi- 1298. Buonamici S, Ottaviani E, Testoni N, et al: Real-time quantitation of minimal resid-
cation of fusion transcripts. Blood 102:2746, 2003. ual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical
1271. Nucifora G, Larson RA, Rowley JD: Persistence of the 8;21 translocation in patients relapse and may identify patients in a curable state. Blood 99:443, 2002.
with acute myeloid leukemia type M2 in long-term remission. Blood 82:712, 1993. 1299. Nucifora G, Birn DJ, Erickson P, et al: Detection of DNA rearrangements in the AML1
1272. Cazzaniga G, Gaipa G, Rossi V, Biondi A: Monitoring of minimal residual disease in and ETO loci and of an AML 1/ETO fusion mRNA in patients with t(8;21) acute
leukemia, advantages and pitfalls. Ann Med 38:512, 2006. myeloid leukemia. Blood 81:1573, 1993.
1273. Freeman SD, Virgo P, Couzens S, et al: Prognostic relevance of treatment response 1300. Maseki N, Miyoshi H, Shimuzu K, et al: The 8;21 chromosome trans-location in acute
measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia is always detectable by molecular analysis using AML 1. Blood
myeloid leukemia. J Clin Oncol 31:4123, 2013. 81:1573, 1993.
1274. Loken MR, Alonzzo TA, Pardo L, et al: Residual disease detected by multidimensional 1301. Kusec R, Laczika K, Knobl P, et al: AML1/ETO fusion mRNA can be detected in
flow cytometry signifies high relapse risk in patients with de novo acute myeloid leu- remission blood samples of all patients with t(8;21) acute myeloid leukemia after che-
kemia: A report from Children’s Oncology Group. Blood 120:1561, 2012. motherapy or autologous bone marrow transplantation. Leukemia 8:735, 1994.
1275. Terwijn M, van Putten WI, Kelder A, et al: High prognostic impact of flow cytomet- 1302. Marcucci G, Livak KJ, Bi W, et al: Detection of minimal residual disease in patients
ric minimal residual disease detection in acute myeloid leukemia: Data from the with AML1/ETO-associated acute myeloid leukemia using a novel quantitative
HOVON/SAKK AML 42A study. J Clin Oncol 31:3889, 2013. reverse transcription polymerase chain reaction assay. Leukemia 12:1482, 1998.
1276. Walter RB, Buckley SA, Pagel JM, et al: Significance of minimal residual disease before 1303. Miyamoto T, Nagafuji K, Akashi K, et al: Persistence of multipotent progenitors
myeloablative allogeneic hematopoietic cell transplantation for AML in first and sec- expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute
ond complete remission. Blood 122:1813, 2013. myelogenous leukemia. Blood 87:4789, 1996.
1277. Bacher U, Zander AR, Haferlach T, et al: Minimal residual disease diagnostics in 1304. Miyamoto T, Nagafuji K, Harada M, et al: Quantitative analysis of AML1/ETO tran-
myeloid malignancies in the post transplant period. Bone Marrow Transplant 42:145, scripts in peripheral blood stem cell harvests from patients with t(8;21) acute myelog-
2008. enous leukaemia. Br J Haematol 91:132, 1995.
1278. Huisman C, de Weger RA, de Vries L, et al: Chimerism analysis within 6 months of 1305. Miyamoto T, Nagafuji K, Harada M, Niho Y: Significance of quantitative analysis of
allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone AML1/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous
Marrow Transplant 39:285, 2007. leukemia. Leuk Lymphoma 25:69, 1997.
1279. Estey E, Pierce S: Routine bone marrow exam during first remission of acute myeloid 1306. Yin JAL, O’Brien MA, Hills RK, et al: Minimal residual disease monitoring by quan-
leukemia. Blood 87:3899, 1996. titative RT-PCR in core binding factor AML allows risk stratification and predicts
1280. Zeleznikova T, Stevulova L, Kovarikova A, Babusikova O: Increased myeloid precur- relapse: Results of the United Kingdom MRC AML-15 trial. Blood 120:2826, 2012.
sors in regenerating bone marrow; implications for detection of minimal residual dis- 1307. Jourdan E, Boisle N, Chevret S, et al: Prospective evaluation of gene mutations and
ease in acute myeloid leukemia. Neoplasma 54:471, 2007. minimal residual disease in patients with core binding factor acute myeloid leukemia.
1281. Campana D, Coustan-Smith E: Detection of minimal residual disease in acute leuke- Blood 121:2213, 2013.
mia by flow cytometry. Cytometry 38:139, 1999. 1308. Takatsuki H, Umemura T, Sadamura S, et al: Detection of minimal residual disease
1282. Adriaansen HJ, Jacobs BC, Kappers-Klunne MC, et al: Detection of residual disease in by reverse transcriptase polymerase chain reaction for the PML/RAR alpha fusion
AML patients by use of double immunological marker analysis for terminal deoxynu- MRNA: A study in patients with acute promyelocytic leukemia following peripheral
cleotidyl transferase and myeloid markers. Leukemia 7:472, 1993. stem cell transplantation. Leukemia 9:889, 1995.
1283. Reading CL, Estey EH, Huh YO, et al: Expression of unusual immunophenotype com- 1309. Zhao L, Chang KS, Estey EH, et al: Detection of residual leukemic cells in patients
binations in acute myelogenous leukemia. Blood 81:3083, 1993. with acute promyelocytic leukemia by the fluorescence in situ hybridization method:
1284. Kita K, Miwa H, Nakase K, et al: Clinical importance of CD7 expression in acute Potential for predicting relapse. Blood 85:495, 1995.
myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma. Blood 1310. Grimwade D, Lo-Coco F: Acute promyelocytic leukemia: A model for the role
81:2399, 1993. of molecular diagnosis and residual disease monitoring in a directing treatment
1285. Porwit-MacDonald A, Janossy G, Ivory K, et al: Leukemia-associated changes iden- approach in acute myeloid leukemia. Leukemia 16:1959, 2002.
tified by quantitative flow cytometry: IV. CD34 overexpression in acute myelogenous 1311. Lo-Coco F, Breccia M, Diverio D: The importance of molecular monitoring in acute
leukemia M2 with t(8;21). Blood 87:1162, 1996. promyelocytic leukaemia. Best Pract Res Clin Haematol 16:503, 2003.
1286. Baer MR, Stewart CC, Dodge RK, et al: High frequency of immunophenotype changes 1312. Tobal K, Moore H, Macheta M, Liu Yin JA: Monitoring minimal residual disease and
in acute myeloid leukemia at relapse: Implications for residual disease detection predicting relapse in APL by quantitating PML-RARalpha transcripts with a sensitive
(Cancer and Leukemia Group B Study 8361). Blood 97:3574, 2001. competitive RT-PCR method. Leukemia 15:1060, 2001.
1287. Voskova D, Schnittger S, Schoch C, et al: Use of five-color staining improves the sen- 1313. Schlenk RF, Döhner K, Krauter J, et al: Mutations and treatment outcome in cytoge-
sitivity of multiparameter flow cytometric assessment of minimal residual disease in netically normal acute myeloid leukemia. N Engl J Med 358:1909, 2008.
patients with acute myeloid leukemia. Leuk Lymphoma 48:80, 2007. 1314. Kronke J, Schlenk RF, Jensen KO, et al: Monitoring of minimal residual disease in
1288. van Rhenen A, Moshaver B, Kelder A, et al: Aberrant marker expression patterns on NPM1-mutated acute myeloid leukemia; a study from the German-Austrian Acute
the CD34+CD38– stem cell compartment in acute myeloid leukemia allows to distin- myeloid leukemia study group. J Clin Oncol 29:2709, 2011.
guish the malignant from the normal stem cell compartment both at diagnosis and in 1315. Chou WC, Tang JL, Wu SJ, et al: Clinical implications of minimal residual disease
remission. Leukemia 21:1700, 2007. monitoring by quantitative polymerase chain reaction in acute myeloid leukemia
1289. Arkesteijn GJ, Erpelinck SL, Martens AC, et al: The use of FISH with chromosome patients bearing nucleophosmin (NPM1) mutations. Leukemia 21:998, 2007.
specific repetitive DNA probes for the follow-up of leukemia patients. Correlations 1316. Sjøholt G, Anensen N, Wergeland L, et al: Proteomics in acute myelogenous
and discrepancies with bone marrow cytology. Cancer Genet Cytogenet 88:69;1996. leukaemia (AML): Methodological strategies and identification of protein targets for
1290. Engel H, Drach J, Keyhani A, et al: Quantitation of minimal residual disease in acute novel antileukaemic therapy. Curr Drug Targets 6:631, 2005.
myelogenous leukemia and myelodysplastic syndromes in complete remission by 1317. Czibere A, Grall F, Aivado M: Perspectives of proteomics in acute myeloid leukemia.
molecular cytogenetics of progenitor cells. Leukemia 13:568, 1999. Expert Rev Anticancer Ther 6:1663, 2006.
1291. Cilloni D, Gottardi E, De Micheli D, et al: Quantitative assessment of WT1 expression 1318. Wang XS, Zhang JW: The microRNAs involved in human myeloid differentiation and
by real time quantitative PCR may be a useful tool for monitoring minimal residual myelogenous/myeloblastic leukemia. J Cell Mol Med 12:1445, 2008.
disease in acute leukemia patients. Leukemia 16:2115, 2002. 1319. Garzon R, Volinia S, Liu CG, et al: MicroRNA signatures associated with cytogenetics
1292. Elmaagacli AH: Molecular methods used for detection of minimal residual disease and prognosis in acute myeloid leukemia. Blood 111:3183, 2008.
following hematopoietic stem cell transplantation in myeloid disorders. Methods Mol
Med 134:161, 2007.

Kaushansky_chapter 88_p1373-1436.indd 1436 9/21/15 11:02 AM